Swedbank AB Purchases 29,128 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Swedbank AB lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 19.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 178,491 shares of the biopharmaceutical company's stock after buying an additional 29,128 shares during the quarter. Swedbank AB owned about 0.16% of Regeneron Pharmaceuticals worth $127,144,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in Regeneron Pharmaceuticals during the third quarter worth $49,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating for the company in a report on Friday, November 1st. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an "outperform" rating and a $1,150.00 target price for the company. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday. Finally, Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Trading Down 0.6 %

Regeneron Pharmaceuticals stock traded down $4.19 during trading hours on Thursday, reaching $683.08. 771,262 shares of the company's stock were exchanged, compared to its average volume of 885,444. The firm's 50 day simple moving average is $723.36 and its 200 day simple moving average is $928.61. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $75.06 billion, a PE ratio of 16.90, a PEG ratio of 1.59 and a beta of 0.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.